Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celldex Therapeutics, Inc.    CLDX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Celldex Therapeutics, Inc. : Celldex Announces Pricing of $90 Million Public Offering of Common Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 02:46am CEST

NEEDHAM, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price to the public of $7.50 per share for an aggregate offering of $90,000,000 of common stock. The proceeds to Celldex from this offering are expected to be approximately $84,345,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Celldex. Celldex has granted the underwriters a 30-day option to purchase up to an aggregate of 1,800,000 additional shares of common stock. All of the shares in the offering are to be sold by Celldex. The offering is expected to close on or about February 11, 2013, subject to customary closing conditions.

Jefferies & Company, Inc. and Leerink Swann LLC are acting as joint book-running managers of the offering. Oppenheimer & Co., Wedbush PacGrow Life Sciences, Brean Capital and Roth Capital Partners, LLC are acting as co-managers of the offering.

Celldex anticipates using the net proceeds from the offering to fund Celldex's clinical trials of its product candidates and for working capital and other general corporate purposes.

A shelf registration statement on Form S-3 relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement relating to these securities, when available, may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, by telephone at 877-547-6340 or by email at [email protected] or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This announcement contains "forward-looking statements"such as those, among others, relating to Celldex's expectations regarding the completion and timing of the closing of the public offering and its anticipated use of net proceeds from the offering. These statements are subject to significant risks and uncertainties; actual results could differ materially from those projected and Celldex cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Celldex will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to Celldex and its business can be found in the "Risk Factors" section of Celldex's Form 10-K, filed with the SEC on March 8, 2012, and in the preliminary prospectus supplement and related prospectus relating to the proposed offering filed with the SEC on February 4, 2013. Celldex undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Celldex's expectations.

CONTACT: Sarah Cavanaugh

         Vice President of IR & Corp Communications

         Celldex Therapeutics, Inc.

         (781) 433-3161

         [email protected]
Source: Celldex Therapeutics, Inc.

News Provided by Acquire Media

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELLDEX THERAPEUTICS, INC.
06/16 CELLDEX THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submissi..
06/16 Celldex Therapeutics Announces Additions to the Board of Directors and Senior..
06/07 CELLDEX THERAPEUTICS, INC. : Today's Research Reports on Stocks to Watch: Cellde..
06/06 Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare C..
06/06 CELLDEX THERAPEUTICS : Presents Promising Overall Survival Data from Phase 2 Stu..
06/05 CELLDEX THERAPEUTICS : Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ..
06/05 Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 201..
06/05 Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single..
05/25 CELLDEX THERAPEUTICS : Patent Issued for Method of Improving Transplant Function..
05/20 U.S. Patents Awarded to Inventors in Iowa (May 20)
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/16 New finance chief at Celldex
06/06 Midday Gainers / Losers
06/06 HEALTHCARE GAINERS / LOSERS AS OF 11 : 00 am
05/09 Celldex beats by $0.01, beats on revenue
05/09 Notable earnings before Wednesday?s open
Advertisement
Financials ($)
Sales 2017 4,26 M
EBIT 2017 -140 M
Net income 2017 -139 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 76,9x
Capi. / Sales 2018 22,8x
Capitalization 328 M
More Financials
Chart CELLDEX THERAPEUTICS, INC.
Duration : Period :
Celldex Therapeutics, Inc. Technical Analysis Chart | CLDX | US15117B1035 | 4-Traders
Full-screen chart
Technical analysis trends CELLDEX THERAPEUT...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 6,50 $
Spread / Average Target 148%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Anthony S. Marucci President, Chief Executive Officer & Director
Larry Ellberger Chairman
Avery W. Catlin CFO, Secretary, Treasurer & Senior Vice President
Tibor Keler Chief Scientific Officer & Executive VP
Thomas Andrew Davis Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLDEX THERAPEUTICS, ..-25.99%328
INCYTE CORPORATION35.91%27 907
QUINTILES IMS HOLDINGS..19.50%19 657
LONZA GROUP27.74%16 010
CELLTRION, INC.--.--%12 252
ALKERMES PLC5.58%8 957
More Results